LOS ANGELES–(BUSINESS WIRE)–Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients. Huntsman…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
As the flu season continues to rage, with the CDC reporting over 23,000 hospitalizations for influenza, several manufacturers have reported shortages of a medicine that can be used to counter it. The American Society of […]
Entrepreneur of The Year Celebrates Ambitious Entrepreneurs Building A Better World ALPINE, Utah, July 12, 2023 /PRNewswire/ — Cheryl Lee Eberting, M.D., the founder and CEO of AZOVA, has been named as a winner of […]
WEST VALLEY CITY, Utah, April 30, 2025 (GLOBE NEWSWIRE) — Nusano, a physics company transforming the production of radioisotopes, today announced the appointment of Rachel Culbertson as Vice President of Supply Chain. Culbertson’s leadership will […]
Copyright © 2026 Biotech Networks
